Regencell Bioscience Holdings Limited (RGC) Stock Overview
Explore Regencell Bioscience Holdings Limited’s financial performance, market position, analyst ratings, and future outlook.
Regencell Bioscience Holdings Limited (RGC)
Key Financials
Key Financials
Market Cap
5.2B
P/E Ratio
-441.10
EPS (TTM)
$-0.01
ROE
-1.61%
RGC Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Regencell Bioscience Holdings Limited (NASDAQ: RGC) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Regencell Bioscience Holdings Limited's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of RGC on the NASDAQ shows an RSI of 82.87, suggesting the stock is in a an overbought condition. Our forecasting models predict a 12-month price target of $17.95 for the NASDAQ listing.
Key metrics behind Regencell Bioscience Holdings Limited's NASDAQ-traded stock include a P/E ratio of -441.10 and a market capitalization of 5.2B. Combined with our AI analysis, these give both institutional and retail investors a clear view of RGC on the NASDAQ.